{"id":26173,"date":"2025-04-17T10:45:04","date_gmt":"2025-04-17T10:45:04","guid":{"rendered":"http:\/\/medexperts.pro\/?p=26173"},"modified":"2025-04-17T11:26:10","modified_gmt":"2025-04-17T11:26:10","slug":"daily-pill-may-work-as-well-as-ozempic-for-weight-loss-and-blood-sugar","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=26173","title":{"rendered":"Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar"},"content":{"rendered":"
<\/div>\n

Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.<\/p>\n

\n
\n
\n

A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.<\/p>\n

The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But GLP-1s are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used.<\/p>\n

\u201cIn the coming decades, 700 million people around the world will have Type 2 diabetes, and over a billion will have obesity,\u201d said Dr. Daniel Skovronsky, Lilly\u2019s chief scientific officer. \u201cInjections cannot be the solution for billions of people around the world.\u201d<\/p>\n

The results Lilly announced came from a clinical trial involving 559 people with Type 2 diabetes who took the new pill or a placebo for 40 weeks. In patients who took orforglipron, blood sugar levels fell by 1.3 to 1.6 percent, about the same amount in that time period experienced by patients taking Ozempic and Mounjaro in unrelated trials. For 65 percent of people taking the new pill, blood sugar levels dropped into the normal range.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

Patients on the new pill also lost weight \u2014 up to 16 pounds without reaching a plateau at the study\u2019s end. Their weight loss was similar to that achieved in 40 weeks with Ozempic but slightly less than with Mounjaro in unrelated trials.<\/p>\n

Side effects were the same as those with the injectable obesity drugs \u2014 diarrhea, indigestion, constipation, nausea and vomiting.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But GLP-1s are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used.\u201cIn the coming decades, 700 million people around the world will have Type 2 diabetes, and over a billion will have obesity,\u201d said Dr. Daniel Skovronsky, Lilly\u2019s chief scientific officer. \u201cInjections cannot be the solution for billions of people around the world.\u201dThe results Lilly announced came from a clinical trial involving 559 people with Type 2 diabetes who took the new pill or a placebo for 40 weeks. In patients who took orforglipron, blood sugar levels fell by 1.3 to 1.6 percent, about the same amount in that time period experienced by patients taking Ozempic and Mounjaro in unrelated trials. For 65 percent of people taking the new pill, blood sugar levels dropped into the normal range.Patients on the new pill also lost weight \u2014 up to 16 pounds without reaching a plateau at the study\u2019s end. Their weight loss was similar to that achieved in 40 weeks with Ozempic but slightly less than with Mounjaro in unrelated trials.Side effects were the same as those with the injectable obesity drugs \u2014 diarrhea, indigestion, constipation, nausea and vomiting.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":26175,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-26173","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lifestyle"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/26173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26173"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/26173\/revisions"}],"predecessor-version":[{"id":26176,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/26173\/revisions\/26176"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/26175"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}